Datapoint: Urovant Prepares for March Gemtesa Launch

Urovant Sciences is gearing up for a March launch of its first FDA-approved drug, Gemtesa, a beta-3 adrenergic receptor agonist which treats overactive bladder (OAB). The OAB market basket is rather crowded, and Gemtesa will have to face off against Astellas Pharma’s leading Myrbetriq, which currently holds preferred status without utilization management restrictions for 45% of all covered lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 1/25/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 17

Datapoint: Oscar to Exit Two States

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: AstraZeneca, Daiichi Score Earlier Breast Cancer Use for Enhertu

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 12

Datapoint: Pfizer Inks Biohaven Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today